Table 1 Clinical–pathological characteristics of EBUS cohort
|  | ALL (n = 12) | pN0 (n = 5) | pN2 (n = 7) |
|---|---|---|---|
Age (years) | |||
 Median (Q1;Q3) | 67 (62;72) | 69 (66;74) | 64 (57;72) |
Gender | |||
 Female | 5 (42%) | 2 (40%) | 3 (43%) |
 Male | 7 (58%) | 3 (60%) | 4 (57%) |
Histology | |||
 LUAD | 8 (67%) | 3 (60%) | 5 (71%) |
 LUSC | 4 (33%) | 2 (40%) | 2 (29%) |
Stage | |||
 IIIA | 12 (100%) | 5 (100%) | 7 (100%) |
NACT regimen | |||
 CDDP + GEM | 10 (83%) | 5 (100%) | 5 (71%) |
 CBDCA + GEM | 1 (8%) | 0 (0%) | 1 (14%) |
 NA | 1 (8%) | 0 (0%) | 1 (14%) |
Number of NACT cycles | |||
 3 cycles | 8 (67%) | 2 (40%) | 6 (86%) |
 4 cycles | 3 (25%) | 3 (60%) | 0 (0%) |
 NA | 1 (8%) | 0 (0%) | 1 (14%) |